Abstract:OBJECTIVE:Cellular response to estradiol is mediated both by estrogen receptor (ER) binding to estrogen response element (ERE) and by non-nuclear actions like activation of signal transduction pathways such as mitogen activated protein kinase (MAPK) pathway. However, the signal transduction of estrogen involving phosphatidylinositol 3-kinase-protein kinase B (PI3K-PKB) is not clear in endometrial carcinoma. Our purpose was to study if PI3K-PKB signaling pathway could be activated rapidly by 17beta-E(2) through non-nuclear action and also, whether PI3K inhibitor, LY294002, could inhibit such non-nuclear action of 17beta-E(2) in endometrial carcinoma cell line Ishikawa. METHODS:Levels of phosphorylated PKB (Ser473 site, p-PKB) and total PKB were examined by western blotting in Ishikawa cells after stimulation with 17beta-E(2) at 1 x 10(-6) mol/L for different time periods and at varied doses for 30 min. Optimal time and appropriate dose for 17beta-E(2) to activate PKB in Ishikawa cells were observed. Inhibitory effect of LY294002 on activation of PKB induced by 17beta-E(2) was also studied. p-PKB/PKB ratio was used to indicate levels of activation of PKB. RESULTS:p-PKB/PKB at 15 min (0.533 +/- 0.029) was significantly higher than the control (0.361 +/- 0.029, P < 0.05). Maximal activation of PKB (maximal levels of p-PKB/PKB) took place at 30 min (0.666 +/- 0.021, P < 0.001) and the activation persisted at least 2 h after stimulation with 1 x 10(-6) mol/L 17beta-E(2) in Ishikawa cells. With increased doses of 17beta-E(2) (vehicle, 1 x 10(-10), 1 x 10(-8), 1 x 10(-6), 1 x 10(-4) mol/L), the activation of PKB (p-PKB/PKB was 0.300 +/- 0.098, 0.312 +/- 0.081, 0.625 +/- 0.100, 0.771 +/- 0.041, 0.902 +/- 0.043 accordingly) increased gradually (in comparison with vehicle, P > 0.05, < 0.05, < 0.05, < 0.001 accordingly). PI3K inhibitor, LY294002 could inhibit the activation of PKB induced by 17beta-E(2) in Ishikawa cells. Levels of PKB (p-PKB/PKB) decreased (0.443 +/- 0.032, 0.415 +/- 0.032, 0.111 +/- 0.035, 0, 0) gradually with increased concentrations (vehicle, 0.1, 10, 50, 100 micro mol/L) of LY294002 (compared with vehicle, P > 0.05, < 0.05, < 0.001, < 0.001) and 50 micro mol/L LY294002 completely blocked the activation of PKB induced by 17beta-E(2). CONCLUSIONS:17beta-estradiol, by non-nuclear action, can activate promptly PI3K-PKB signaling pathway in endometrial carcinoma cell line, Ishikawa. This action of 17beta-E(2) is PI3K dependent and can be inhibited or blocked by LY294002.

Growth and Activation of PI-3K/PKB and Akt by Stromal Cell-Derived Factor 1α in Endometrial Carcinoma Cells with Expression of Suppressor Endoprotein PTEN

Role of Suppressor Encoprotein PTEN in IGF-1 Induced Activation of ERK in Endometrial Carcinoma Cells

Stromal Cell-Derived Factor 1 Alpha Stimulates Human Endometrial Carcinoma Cell Growth Through the Activation of Both Extracellular Signal-Regulated Kinase 1/2 and Akt

Activation of Signaling Transduction Pathways Induced by Stromal Cell Derived Factor-1Α in Endometrial Carcinoma Cells

Effect of Different PTEN Status on PI3K/AKT Pathway of Endometrial Cancer Cell Lines

Differential Sensitivity of Human Endometrial Carcinoma Cells with Different PTEN Expression to Mitogen-Activated Protein Kinase Signaling Inhibits and Implications for Therapy

Effect of Suppressor Oncoprotein PTEN on EGF Induced Activation of ERK in Endometrial Carcinoma Cells

Role of Phosphatase PTEN in the Activation of Extracellular Signal-Regulated Kinases Induced by Estradiol in Endometrial Carcinoma Cells.

[Effect of Signal Transduction Inhibitors on Human Endometrial Carcinoma Cells with Differential PTEN Gene Expression].

Igfbp-Rp1 Acts As A Potential Tumor Suppressor Via the Suppression of Erk Signaling Pathway in Endometrial Cancer Cells

17Β-Estradiol Activates PI3K/Akt Signaling Pathway by Estrogen Receptor (Er)-Dependent and ER-independent Mechanisms in Endometrial Cancer Cells

[Significance of Phosphoinositide 3 Kinase/akt Pathway Alterations in Endometrial Carcinoma].

Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer.

[Activation of Phosphatidylinositol 3-Kinase-protein Kinase B (PI3K-PKB) Induced by 17Beta-Estradiol in Endometrial Carcinoma Cell (Ishikawa)].

Signal transduction pathway of cell proliferation induced by EGF and TGF-α in endometrial cancer

Effects of PTEN on the migration and invasion of endometrial carcinoma cells

Normal Endometrial Stromal Cells Regulate Survival and Apoptosis Signaling Through PI3K/AKt/Survivin Pathway in Endometrial Adenocarcinoma Cells in Vitro

[Effect of Gonadotropin-Releasing Hormone-I Agonist and Gonadotropin-Releasing Hormone-Ii on Endometrial Carcinoma Cell Lines with Different States of PTEN].

Data from High Frequency of <i>pik3r1</i> and <i>pik3r2</i> Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer ishikawa cells

AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma